Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
31.01
+2.19 (7.60%)
At close: Apr 20, 2026, 4:00 PM EDT
31.04
+0.03 (0.10%)
After-hours: Apr 20, 2026, 7:59 PM EDT
Hims & Hers Health Revenue
In the year 2025, Hims & Hers Health had annual revenue of $2.35B with 59.00% growth. Hims & Hers Health had revenue of $617.82M in the quarter ending December 31, 2025, with 28.41% growth.
Revenue (ttm)
$2.35B
Revenue Growth
+59.00%
P/S Ratio
3.01
Revenue / Employee
$961,358
Employees
2,442
Market Cap
7.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.35B | 871.13M | 59.00% |
| Dec 31, 2024 | 1.48B | 604.51M | 69.32% |
| Dec 31, 2023 | 872.00M | 345.08M | 65.49% |
| Dec 31, 2022 | 526.92M | 255.04M | 93.81% |
| Dec 31, 2021 | 271.88M | 123.12M | 82.77% |
| Dec 31, 2020 | 148.76M | 66.20M | 80.18% |
| Dec 31, 2019 | 82.56M | 55.88M | 209.45% |
| Dec 31, 2018 | 26.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Lantheus Holdings | 1.54B |
| Alkermes | 1.48B |
| Prestige Consumer Healthcare | 1.10B |
| Supernus Pharmaceuticals | 718.95M |
HIMS News
- 3 days ago - What's Going On With Hims & Hers Shares - Benzinga
- 4 days ago - RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves - CNBC
- 4 days ago - Hims rises as FDA considers broader peptides access; analysts see long-term win - Reuters
- 4 days ago - Hims & Hers surges 4% as peptide policy shift unlocks growth - Invezz
- 4 days ago - Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time. - Barrons
- 5 days ago - Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides - Market Watch
- 7 days ago - Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026 - Business Wire
- 12 days ago - HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire